7:30 Continental Breakfast, Poster Viewing & Discussion

8:30 Keynote Address: George Poste, SmithKline Beecham
Pharmacogenetics: Individual genetic diversity, population segmentation and rational therapy

Technological Approaches for Analyzing Genetic Variation I
Session Chair: Stanley T. Crooke, Isis Pharmaceuticals

9:00 Chris Hanna, Transgenomic, Inc.
SNP mapping-An overview of its potential and challenges

9:30 Debbie Nickerson, University of Washington
High-throughput sequencing and SNP detection

10:00 Daniel Cohen, Genset
Whole genome association studies in humans

10:30 Coffee Break, Poster Viewing & Discussion

Technological Approaches for Analyzing Genetic Variation II

11:00 Keith W. Jones, Affymax Research Institute
Association genetics

11:30 Natalie Jean Warner, Axys Pharmaceuticals, Inc.
Use of pharmacogenomics in clinical trial design

12:00 Glenn A. Miller, Genzyme
Expression technologies and genotyping. Problem solving in drug development

12:30 Luncheon

1:15 Luncheon Address: Klaus Lindpaintner, F. Hoffmann-La Roche Ltd.
Genetics and Drug Discovery: Fact or Fancy, Promise or Peril?

Technological Approaches for Analyzing Genetic Variation III

2:00 Reid Townsend, Oxford GlycoSciences
Applications of proteomics in drug development

2:30 Allen D. Roses, Glaxo Wellcome
Validating high-density SNP mapping for gene identification and patient selection

3:00 Robert J. Lipshutz, Affymetrix, Inc.
DNA probe arrays for pharmacogenomic discovery and therapeutic management

3:30 Coffee Break, Poster Viewing & Discussion

Technological Approaches for Analyzing Genetic Variation IV

4:00 Charles R. Cantor, Sequenom, Inc.
Automated MS analysis of DNA sequence polymorphisms

4:30 Kleanthis G. Xanthopoulos, Aurora Biosciences Corp.
Integrating genome-wide functional analysis with high-throughput systems for pharmacogenomics

5:00 Mark Egerton, Incyte Pharmaceuticals, Inc.
Applications for pharmacogenomics as a tool for drug discovery and development

5:30 Wine & Cheese Reception: Werner Kalow, University of Toronto
Pharmacogenomics: A historical perspective

7:30 Continental Breakfast, Poster Viewing & Discussion

8:30 Keynote Address: Arno G. Motulsky, University of Washington
Pharmacogenetics, ecogenetics and pharmacogenomics: Approaches to polygenic mechanisms in drug metabolism and disease etiology

Drug Metabolism

9:00 Kim Brøsen, Odense University
Cytochrome P4502D6: Its role in disease, drug development and pharmacotherapy

9:30 Richard M. Weinshilboum, Mayo Medical School
Methylation pharmacogenomics

10:00 Coffee Break, Poster Viewing & Discussion

Oncology

10:30 Michael Kauffman, Millennium Predictive Medicine
Melastatin: a novel gene that correlates with the potential for melanoma metastasis

11:00 Olli-P. Kallioniemi, National Human Genome Research Institute
Tissue microarrays for molecular profiling of tumor specimens

11:30 Luncheon

12:15 Luncheon Address: B. Michael Silber, Pfizer, Inc.
The challenge to pharmaceutical R&D: Relating genetic diversity, disease phenotypes, and response outcomes

Viral, Neurologic & Cardiovascular Diseases

1:00 Joseph P. Miletich, Washington University
Factor V Leiden and risk for venous thromboembolism: Impact on pharmacotherapy

1:30 Mickey S. Urdea, Chiron Diagnostics
Hepatitis C

2:00 Stephen B. Liggett, University of Cincinnati College of Medicine
Variation in response to therapy and disease modification due to polymorphisms of adrenergic receptors

2:30 Anne N. Murphy, MitoKor
Mitochondrial dysfunction in neurodegenerative disease

3:00 Coffee Break

3:30 Ken Conway, Millennium Predictive Medicine Fred D. Ledley, Variagenics, Inc. Rochelle M. Long, NIGMS, NIH Gualberto Ruaņo, Genaissance Pharmaceuticals, Inc. Elizabeth Silverman, BancBoston Robertson Stephens Brian B. Spear, Abbott Laboratories
Roundtable Discussion: Building the Business Infrastructure

4:30 Conference Ends